Scientific output of the emerging Cuban biopharmaceutical industry: a scientometric approach by Arencibia-Jorge, Ricardo et al.
Scientific output of the emerging Cuban biopharmaceutical 
industry: a scientometric approach 
 
Ricardo Arencibia-Jorge1a, Elena Corera-Alvarez2, Zaida Chinchilla-Rodríguez3 and 
Félix de Moya-Anegón4 
1ricardo.arencibia@cnic.edu.cu 
National Center for Scientific Research (CNIC), Ave. 25 and 158, Havana (Cuba) 
2elena.corera@csic.es 
SciMago Research Group, Institute of Policies and Public Goods, CCHS-CSIC, Madrid (Spain) 
3zaida.chinchilla@csic.es 
SciMago Research Group, Institute of Policies and Public Goods, CCHS-CSIC, Madrid (Spain) 
4felix.moya@scimago.es 
SciMago Research Group, Institute of Policies and Public Goods, CCHS-CSIC, Madrid (Spain) 
Abstract 
Cuba has developed a biopharmaceutical sector that involves some of the country’s most relevant 
scientific institutions. Despite the severe constraints on resources resulting from the U.S. 
embargo, the results achieved by this sector have contributed to put the country’s health indicators 
at the same level of high-income nations. Recently, the creation of BioCubaFarma as a cluster of 
high-technology enterprises organized around a closed cycle model becomes one of the most 
relevant efforts of the Island in order to make biopharmaceuticals one of the country’s leading 
export earners. The main aim of the current paper was to characterize BioCubaFarma through a 
battery of Scopus-based bibliometric indicators. A comparison with the most productive 
multinational pharmaceutical companies was made. Regression analysis of annual productivity, 
number of citations, scientific talent pool, innovative knowledge and other citation-based 
indicators was performed. Differences and similarities between BioCubaFarma and multinational 
companies in four Scopus subject categories related to this sector were identified. The most 
productive and visible institutions from BioCubaFarma were also characterized. Qualified human 
resources, innovative knowledge, leadership, high specialization in the field of vaccines 
development and non-dependence of international collaboration are strengths of the organization. 
However, it is still necessary to increase the number of articles published in highly visible journals 
with the aim to achieve a better citation-based performance. Moreover, to increase the 
contributions from less-productive institutions, more clinical research published in medical 
journals and more collaboration with universities and health institutions could also have positive 
benefits for BioCubaFarma’s pipelines and portfolios.  
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Introduction 
Far from the monopoly of media, and despite the severe constraints on resources resulting 
from the US embargo, Cuba has developed a biopharmaceutical sector that involves some 
of the country’s most relevant scientific institutions. The results achieved by this sector 
have contributed to put the country’s health indicators at the same level of high-income 
nations, with extraordinary success in low infant, child and maternal mortality rates and 
healthy-live expectancy (Cooper, Kennelly, & Ordunez-Garcia, 2006; Lage, 2008; Sáenz, 
2005). 
From a scientometric perspective Cuban scientific output at macro level have been 
recently analysed (Araujo-Ruiz, Van Hooydonk, Torricella-Morales, & Arencibia-Jorge, 
2005; Arencibia-Jorge & de Moya-Anegón, 2010; Chinchilla-Rodríguez, Arencibia-
Jorge, de Moya-Anegón, & Corera-Álvarez, 2015), with emphasis in literature on health 
science (Arencibia-Jorge, Vega-Almeida, Chinchilla-Rodríguez, Corera-Álvarez, & 
Moya-Anegón, 2012; Cañedo Andalia et al., 2014; Cañedo Andalia, Pérez Machín, 
Guzmán Sánchez, & Rodríguez Labrada, 2010; Zacca-González, Chinchilla-Rodríguez, 
Vargas-Quesada, & de Moya-Anegón, 2015; Zacca-González, Vargas-Quesada, 
Chinchilla-Rodríguez, & De Moya-Anegón, 2014). However, none of them have been 
focused on topics related to biotechnology and the pharmaceutical sector, or specifically 
dedicated to analyse the Cuban biopharmaceutical industry, recently improved since the 
creation of BioCubaFarma as a new cluster of high-technology enterprises belonging to 
this sector. 
The pharmacological domain has been studied with high frequency by bibliometric 
studies, due to the important medical and economic repercussions of research in this area. 
At country level, Bordons and colleagues studied the Spanish scientific output, using a 
citation-based indicator (the Expected Impact Factor) to identify the potential influence 
of Spanish research on the international scientific community (Bordons, Barrigon, & 
Mendez, 1996; Bordons & Zulueta, 1997; Bordons, Zulueta, & Barrigon, 1998). They 
found during the nineties the subfield Pharmacology & Pharmacy in a very dynamic 
stage, with a great increase in the number of researchers, starting of new teams and 
consolidation of others (Bordons et al., 1998).  
Biochemistry & Molecular Biology and Pharmacology & Pharmacy were among the 
three most productive research fields in the Spanish biomedical research (Cami, Zulueta, 
Fernandez, Bordons, & Gomez, 1997; Gomez, Fernandez, Bordons, & Morillo, 2004). 
This protagonist role of pharmacological research was also identified in Iran 
(Mohammadhassanzadeh et al., 2010). Ammed and colleagues analyzed the Indian 
pharmacological research using Scopus as data source, and comparing the Indian 
performance with the scientific output of the 15 most productive countries (Ammed, 
Gupta, & Gupta, 2014). In the same way, Ding and colleagues evaluated the productivity 
of China during the first decade of the XXI Century in relation to ten representative 
countries (Ding, Ge, Wu, & Zheng, 2013). In UK, Science Parks and Research Parks were 
identified as successful infrastructures in fostering cooperation and research production, 
with strong links to universities (Minguillo, Tijssen, & Thelwall, 2015).  
Patent research using bibliometric methods in the context of the pharmaceutical industry 
were remarked by Huang and colleagues (Huang, Fang, & Chang, 2011). Some studies 
applied non citation-based indicators to analyze pharmaceutical domains in order to 
assess the probability of drug success (Kissin & Bradley, 2011, 2012), or publication 
trends of pharmaceutical science faculty members at research-intensive colleges and 
schools of pharmacy (Thompson & Nahata, 2012). Although, comparative studies of 
Scopus and Web of Science to evaluate Pharmacy Journals have been developed (Gorraiz 
& Schloegl, 2008). However, internationalization processes and cooperation patterns 
have receiving wide attention during the last ten years from a scientometric perspective 
(Calero, Van Leeuwen, & Tijssen, 2007; Cantner & Rake, 2014; Natsukawa, Gemba, & 
Ishida, 2013; Olmeda-Gomez, Perianes-Rodriguez, Ovalle-Perandones, & Moya-
Anegon, 2008; Perianes-Rodriguez, Olmeda-Gomez, Ovalle-Perandones, Chinchilla-
Rodriguez, & Moya-Anegon, 2011; Tijssen, 2009; Zhao & Guan, 2011).  
The important role of private enterprises in scientific development and innovation 
(Perianes-Rodriguez et al., 2011), the central position of US companies in 
pharmacological research (Calero et al., 2007; Tijssen, 2009), the intra- and inter-
organizational patterns of research cooperation linkages (Calero et al., 2007; Natsukawa 
et al., 2013), and the university-enterprise-government inter-relationships (Olmeda-
Gomez et al., 2008), were topics analyzed in these studies, where largest multinational 
pharmaceutical companies have been protagonists.  
During the last 30 years, Cuba developed a strong pharmaceutical industry focused in 
biotechnology products, generics and alternative medicines. The industry was organized 
around a closed cycle model, whereby research, development, production, marketing, and 
follow-up evaluations for a given product are carried out within the same administrative 
unit (Lage, 2006, 2008). 
The foundation of the National Center for Scientific Research (CNIC) in 1965 was the 
first step in this race. The developing of qualified human resources was the main aim of 
CNIC’s laboratories, where most of the current Cuban biotech leaders started their 
research activities. In 1981 a team of Cuban scientists trained by Dr. Kari Cantell 
(Finland) developed the capacity to isolate Interferon from human cells in large quantities, 
and the government established the Biological Front, an interdisciplinary forum to 
facilitate de development of Cuban biotechnology (Lopez et al., 2007; López Mola et al., 
2006; Sáenz, 2005).  
From 1986 to 1990 important scientific centers were inaugurated, as the Center for 
Genetic Engineering and Biotechnology (CIGB, 1986), the Center of Immunoassay (CIE, 
1987), the Finlay Institute (IFinlay, 1991), the Center for Molecular Immunology (CIM, 
1994), among others. All these institutions were integrated in the Western Havana 
Scientific Pole, a cluster of 52 institutions and enterprises related to biotechnology that 
received from the government an invest of more than $1 billion dollars during the worst 
economic crisis of the country, after the collapse of the Soviet Union (Castillo, Caballero, 
& Triana, 2013; Pérez Ones & Jover, 2009). 
This biocluster achieved relevant results during the next two decades: the world´s first 
vaccine against Meningitis B, a cholesterol-lowering drug derived from sugarcane 
without side effects (PPG), a vaccine against recombinant Hepatitis B, a recombinant 
streptokinase product obtained from DNA for used in acute myocardial infarctions, the 
world´s first synthetic vaccine against Haemophilus influenzae type B (Quimi-Hib), and 
recently, therapeutic cancer vaccines based on monoclonal antibodies (CimaVax-EGT, 
Theraloc, etc.), and a recombinant growth factor used in the treatment of diabetic foot 
ulcers (Heberprot-PE).  
In 2013, the West Havana biocluster and Quimefa, the most important Cuban 
pharmaceutical company, were integrated to create BioCubaFarma. In the context of the 
Cuban economic model reform, this strategic fusion improved the structure of the Cuban 
biotechnological and pharmaceutical industry. The aim is not only to enhance the 
coverage of national drug demands, but also to create solid worldwide partners and 
distributors, to introduce products in new markets, and to increase the sales over five 
billion dollars in the near future, which is probably to make biopharmaceuticals the 
country’s leading export earner. 
Despite the economic revenues obtained from the sales of its products, the research 
philosophy of BioCubaFarma’s project is diametrically opposed to the market policies of 
the big pharmaceutical industry. First, the priority is to maintain the country’s health 
standards, minimizing Cuba’s dependency on pharmaceutical imports (Lage, 2006, 
2008). On the other hand, whereas de dominant practice among larger pharmaceutical 
companies in industrialized countries is to outsource manufacturing, the Cuban system 
maintains local production facilities, creating additional employment opportunities at 
home. Also, the Cuban biopharmaceutical industry hardly uses money for publicity, 
which is an activity with high expenses in budgets of multinational corporations (Castillo 
et al., 2013; Lage, 2006). 
The main aim of the current paper is to characterize the scientific production of 
BioCubaFarma during a pre-foundational period (2003-2013). BioCubaFarma’s 
performance is analysed at national level, and it is compared with the performance of the 
15 most productive multinational pharmaceutical companies. A battery of Scopus-based 
bibliometric indicators to analyse activity, specialization, impact, collaboration, 
leadership, and excellence of these institutions, is used. Differences and similarities are 
identified and discussed.   
 
Material and Methods 
The SCImago Institutions Rankings (SIR), based on Scopus data and developed by the 
SCIMago Research Group (Spain), was used to retrieve output developed by Cuban 
institutions with more than 25 published papers per year. The whole output of 
BioCubaFarma and the scientific production of its most productive institutions were also 
retrieved. For comparative purposes, data of the 15 most productive multinational 
pharmaceutical companies were compiled, using not only global output, but also the 
performance of each institution in the following Scopus subject categories:  
 Pharmacology, Toxicology & Pharmacy (PTP) 
 Immunology and Microbiology (I&M) 
 Biochemistry, Genetics & Molecular Biology (BG&MB) 
 Medicine 
A set of bibliometric indicators, most of them developed by the SCImago Research 
Group, were used to analyze scientometric characteristics of the studied institutions: 
Output (Ndoc): Total number of documents published in scholarly journals indexed in 
Scopus. 
Annual Productivity (AP): Total number of documents published per year during the 
period 2003-2013. 
Citations (Ncit): Total number of citations received by all documents published in 
scholarly journals indexed in Scopus. 
Cited documents (% Cited doc): Percentage of documents with at least one citation 
received during the period 2003-2013. 
International Collaboration (% Int Coll): Institution's output ratio produced in 
collaboration with foreign institutions. The values are computed by analyzing an 
institution's output whose affiliations include more than one country address (Guerrero-
Bote, Olmeda-Gómez, & Moya-Anegon, 2013).   
Normalized Impact (NI): Normalized Impact of led output is computed using the 
methodology established by the Karolinska Intitutet in Sweden where it is named "Item 
oriented field normalized citation score average". The normalization of the citation values 
is done on an individual article level (Rehn, Kronman, & Wadskog, 2007). The values (in 
decimal numbers) show the relationship between an institution's average scientific impact 
and the world average set to a score of 1, --i.e. a NI score of 0.8 means the institution is 
cited 20% below world average and 1.3 means the institution is cited 30% above average.  
High Quality Journals (% Q1): Ratio of publications that an institution publishes in the 
most influential scholarly journals of the world, those ranked in the first quartile (25%) 
in their categories as ordered by SCImago Journal Rank (SJRII) indicator. 
Excellence (% Exc): Excellence rate that indicates the amount (in %) of an institution’s 
scientific output that is included into the set of the 10% of the most cited papers in their 
respective scientific fields. It is a measure of high quality output of research institutions 
(Bornmann, Moya-Anegon, & Leydesdorff, 2012).  
Leadership (% Lead): Leadership rate that indicates the percentage of an institution’s 
output as main contributor, that is, the amount of papers in which the corresponding 
author belongs to the institution (Moya-Anegon, Guerrero-Bote, Bornmann, & Moed, 
2013). 
Excellence with Leadership (% EwL): Excellence with Leadership indicates the amount 
of documents in the Excellence rate in which the institution is the main contributor. 
Scientific Talent Pool (STP): Total number of authors from an institution in the total 
publication output of that institution during a particular period of time. 
Innovative Knowledge (IK): Scientific publication output from an institution cited in 
patents. Based on PATSTAT (http://www.epo.org). 
Specialization Index (Spec): Based on the activity index (Frame, 1977), it is calculated 
to identify thematic specialization of institutions through the following procedure: 
Spec = (Ndoc company (domain) / Ndoc company (total)) / (Ndoc company (domain) / Ndoc company (total)) 
Attractivity Index (AI): Based on the countries’ Attractivity Index (Braun & Schubert, 
1997), it is calculated to determine the visibility of companies through the following 
procedure: 
AI = (Ncit company (domain) / Ncit company (total)) / (Ncit company (domain) / Ncit company (total)) 
In the last two indicators, values higher than 1 express more specialization and visibility 
of companies in the analyzed domains with respect to the world. To facilitate the 
representation of specialization and attractivity indexes, a scale of values between -1 and 
1 were used (Glanzel, 2000), where the 0 value is the position of the world in the studied 
thematic domains. 
Microsoft Excel graphs were used to compare companies’ performances, and regression 
patterns among the global indicators of the studied companies were analyzed. Finally, an 
analysis of the most productive institutions belonging to BioCubaFarma was made, in 
order to check which of them are determinant in the global BioCubaFarma’s performance. 
 
Results and Discussion 
The biopharmaceutical sector has been a protagonist role in Cuban scientific output 
during more than a decade. Organizations belonging to BioCubaFarma generated 2 908 
articles published in Scopus-indexed journals during the period 2003-2013, which 
allowed this company to reach the second position at national level in the SciMago 
Institutions Rankings (SIR), just two years after its foundation (Table 1). 
 
Table 1. Scientometric performance of the Cuban most productive institutions (Scopus, 2003-
2013). 
 Ndoc AP Ncit 
% 
Cited 
doc 
%  
Int 
Coll 
NI %  Q1 
% 
Exc 
% 
Lead 
% 
EwL STP IK 
UH 2993 272,1 18824 63,78 66,46 0,55 37,05 5,35 44,27 1,24 2137 42 
BCF 2908 264,4 22285 62,00 30,81 0,51 28,71 4,26 68,23 2,06 4079 113 
ISCMH 1353 123,0 2186 20,33 13,67 0,16 7,24 1,55 64,6 0 1740 1 
UCLV 1141 103,7 8887 59,33 64,5 0,73 30,94 12,1 55,74 6,57 1084 13 
IPK 1064 96,7 7571 58,18 32,42 0,48 23,4 5,36 69,74 1,88 1202 13 
HHA 666 60,5 1149 23,12 10,21 0,11 5,26 1,2 66,67 0,15 1023 4 
UO 639 58,1 2711 60,56 73,55 0,5 27,23 6,73 53,36 2,5 561 9 
ICA 577 52,5 495 39,51 23,22 0,11 1,73 0 77,47 0 340 0 
CUJAE 494 44,9 1753 45,95 65,79 0,47 24,49 6,68 42,91 0,81 464 3 
ICIMAF 335 30,5 1508 61,79 72,24 0,53 36,12 6,87 45,07 2,69 163 0 
UMCC 307 27,9 3541 72,31 68,08 1,01 39,74 13,7 63,52 5,54 185 13 
IHI 281 25,5 273 19,22 5,34 0,06 3,2 0,36 84,34 0 365 1 
 
BioCubaFarma shown a productivity of around 264 papers per year, only behind the 
University of Havana (UH), all-time leader of Cuban scientific activity (Araujo-Ruiz et 
al., 2005; Arencibia-Jorge & de Moya-Anegón, 2010; Sancho, Bernal, & Gálvez, 1993). 
The 62 % of the scientific articles were cited. International collaboration involve only 
30,81 % of papers, while 68,23 % had researchers from BioCubaFarma’s institutions as 
corresponding authors.  
In the context of the Cuban most productive institutions during the studied period (more 
than 25 papers per year), BioCubaFarma achieved the eighth position in high cited articles 
(% Exc), and the fifth position according to the impact of research (NI), publication in 
high visible journals (% Q1), and leadership of the most cited articles (% EwL). These 
citation-based indicators are leaded by universities from Matanzas (Universidad de 
Matanzas “Camilo Cienfuegos”, UMCC) and Villa Clara (Universidad Central de Las 
Villas, UCLV), which were clearly the most visible Cuban institutions (Figure 1). In 
almost all university cases, with the solely exception of the Instituto Superior de Ciencias 
Médicas de La Habana (ISCMH), international collaboration is determinant to reach 
good citation-based performances.  
Compared with the most productive Cuban institutions, BioCubaFarma’s behaviour 
exposed characteristics that become strengths. First, visibility was not dependent of the 
international collaboration (similar to the Instituto de Medicina Tropical “Pedro Kourí”, 
IPK), which is an evidence of the protagonist role of BioCubaFarma’s companies in the 
sector development. Second, it was the leader according STP indicator, which implies 
that many researchers from BioCubaFarma are involved in published articles. Third, it 
was leader according to the IK index, thanks to a total of 113 BioCubaFarma’s papers 
cited by international patents. On the other hand, similar characteristics were observed in 
leadership, where Cuban institutions shown higher percentages. 
 
Figure 1. Leadership, international collaboration, output in high visible journals, excellence and 
normalized impact of the most productive Cuban institutions (Scopus, 2003-2013). 
 
Another picture is offered by the comparison of BioCubaFarma with the 15 most 
productive multinational biopharmaceutical companies (Table 2). While 28 % of 
BioCubaFarma’s scientific literature was published in high visible journals (Q1 of 
Scopus), multinationals shown values over 60 %. This behaviour had a clear repercussion 
on the impact values. The range of excellence (20-30 %), excellence with leadership (5-
10 %), cited papers (>80 %) and normalized impact (1.5-2.6) in multinationals are clearly 
higher than BioCubaFarma’s values (4.26 %; 2.06 %; 62 %; and 0,51, respectively). 
Low international collaboration value is a characteristic that share BioCubaFarma with 
multinationals. But it is in leadership when BioCubaFarma revealed a significant 
difference with the international competence. To be the leader of research is an advantage 
for BioCubaFarma. But the strategies of multinational companies have also positive 
benefits on R&D results. The percentage of non-leaded papers of these companies is 
distributed among research departments of universities, university hospitals or private 
clinics where they invest a proportion of their R&D budget. This politics ensure advances 
not only in the growth of new research lines and products, but also in the acquisition of 
qualified human resources for companies. Therefore, to sacrifice leadership in order to 
create strong links with universities to enhance pipelines and research portfolios is a 
positive way, and must be used with most frequency by BioCubaFarma’s enterprises.   
The size factor put in evidence the positive linear relationship between annual 
productivity, number of citations, scientific talent pool and innovative knowledge (Figure 
2). However, it is clear the classic link between expected and real visibility: higher the 
percentage of articles published in Q1 journals is, higher is also the percentage of articles 
among the most cited literature of a discipline, and the normalized impact of the whole 
scientific output. 
Table 2. Scientometric performance of Biocubafarma and the most productive multinational 
biopharmaceutical companies (Scopus, 2003-2013). 
 Ndoc AP Ncit 
% 
Cited 
doc 
% 
Coll 
Int NI 
% 
Q1 
% 
Exc 
% 
Lead 
% 
ExL STP IK 
Pfizer 20987 1907,9 596206 89,1 32,52 1,86 69,82 23,61 44,66 7,79 18371 1589 
Merck 16432 1493,8 537142 90,56 34,03 1,96 74,24 24,25 51,66 9,66 14576 1627 
GSK 15308 1391,6 447094 89,88 42,83 1,93 73,03 23,77 36,03 6,54 12372 1112 
Novartis 14943 1358,5 534877 89,83 55,8 2,18 75,53 29,43 36,26 9,16 11350 1361 
FH-LR 10984 998,5 451747 90,54 43,27 2,6 77,13 30,7 39,66 10,5 9943 1170 
AZ 10550 959,1 296514 90,64 44,84 1,84 72,33 22,84 34,99 6,12 7942 608 
ELI 8833 803,0 257110 88,71 36,92 1,88 71,8 23,21 43,64 7,98 6035 597 
Bayer 7447 677,0 180426 83,95 44,23 1,69 61,72 20,23 36,19 5,05 5759 607 
BMS 5548 504,4 165791 88,27 27,88 2,38 70,03 24,33 47,91 7,85 113 502 
J&J 5127 466,1 143874 88,36 37,04 1,8 69,81 21,92 46,52 7,51 4461 533 
Amgen 5125 465,9 167667 90,03 28,9 2,15 74,09 27,42 41,68 8,45 4384 484 
Abbott 5022 456,5 133927 88,49 28,69 1,72 68,3 22,27 49,52 7,74 4301 529 
Sanofi-Av 4801 436,5 126041 88,71 42,43 1,71 68,05 21,87 27,64 4,53 4690 359 
BI 3771 342,8 104967 85,89 45,9 2,29 68,52 25,07 38,53 7,19 3027 282 
BCF 2908 264,4 22285 62 30,81 0,51 28,71 4,26 68,23 2,06 4079 113 
 
Figure 2. Regression analysis of global indicators used to measure companies performances 
(Scopus, 2003-2013). 
  
  
  
 
The analysis of the most covered subject categories in BioCubaFarma’s literature offers new 
interesting trends (Figures 3 and 4). The Cuban biocluster shares specialization (activity 
index) and visibility (attractivity index) patterns with multinational companies in the 
fields of PTP and BG&MB, which illustrate its advances in pharmaceuticals and 
biotechnology-based products (Figure 3). I&M is the subject category where 
BioCubaFarma is absolute leader, thanks to the protagonist role of therapeutic vaccines 
in the company’s pipeline. But the publication efforts in medical journals are low 
compared with those developed by multinational companies, which could be evidence of 
two elements: 
 An early stage of a big proportion of BioCubaFarma’s research projects. 
 An insufficient visibility of clinical research. 
 
Figure 3. Thematic Specialization, Attractivity Index and Normalized Impact of the studied 
companies in four selected Scopus subject categories (2003-2013). 
 
 
 
 
 
The first element is a strong point of BioCubaFarma, taking into account the new 
international context for Cuban economy, especially after the normalization of 
relationships between Cuba and United States governments. To enhance the coverage of 
national drug demands, to create solid worldwide partners and distributors, to introduce 
products in new markets, and to increase sales, requires also to have in plan the 
introduction of new products as a long time strategy, in order to build a sustainable way 
to development. 
The second element is clearly a weakness. The results of clinical trials, especially when 
they revealed positive effects and involve huge amounts of patients, must be published in 
the best medical journals. This stimulates the interest of national and international 
research groups with the aim to test products in new population samples, which is also a 
guarantee for worldwide registration of products for sale.   
Anyway, the low normalized impact of BioCubaFarma’s output in each of the subject 
categories studied is a handicap. With low expenses in publicity, and even under 
constraints on resources resulting from the US embargo, it is necessary in terms of 
publication in high visible journals (% Q1) to increase the values observed in Figure 4, 
with the aim to revert this behaviour.  
BioCubaFarma shown the highest values of leadership and the lowest values of 
international collaboration, expected visibility and excellence in all subject categories 
studied. Multinational companies exposed significant values of leadership in PTP (50-65 
%) and BG&MB (40-60 %), with low values of international collaboration (<40 %) in 
both categories; in contrast, international collaboration was high in I&M (>40 %) and 
Medicine (>40 %, with the solely exception of Amgen and Abbott Laboratories), 
categories where leadership values reached percentages around 40 % or lowest. This 
dependency (or not) of international collaboration is apparently not related to the expected 
visibility of research: multinational companies shown higher values of publications in the 
most visible journals of the four categories, but the expected visibility is lowest in I&M 
(≈40-60 %) than in Medicine (60-80 %). Anyway, Medicine is the subject category where 
BioCubaFarma’s enterprises and multinational companies achieved the best measures of 
expected visibility and research excellence. 
Figure 4. Leadership, international collaboration, output in high visible journals and excellence 
of the studied companies in four selected Scopus subject categories (2003-2013). 
 
 
 
 
Inside the organization, the picture also offers interesting views. Only 18 enterprises 
contribute to the BioCubaFarma’s scientific output covered by Scopus, and from them, 
14 produced more than one paper per year (Table 3). Only seven presented an annual 
productivity higher than 20 papers per year, which were the core of institutions 
responsible for the most relevant R&D achievements.  
 
Table 3. Scientometric performance of institutions belonging to Biocubafarma (Scopus, 2003-
2013). 
 Ndoc AP Ncit 
% 
Cited 
doc 
%  
Int 
Coll 
NI %  Q1 
%  
Exc 
% 
Lead 
% 
EwL STP IK 
CIGB 906 82,4 7778 69,43 28,04 0,61 34,77 4,19 71,74 2,54 1343 60 
CNIC 526 47,8 3734 66,35 24,14 0,43 23,76 3,04 67,3 0,76 557 12 
CIM 331 30,1 3407 73,72 34,74 0,66 42,3 7,25 54,68 3,32 352 16 
CNC 294 26,7 4129 74,49 53,06 0,82 48,98 10,54 45,58 5,1 285 5 
CIDEM 266 24,2 300 27,44 10,15 0,13 4,51 0,75 78,57 0,38 410 0 
IFINLAY 265 24,1 1568 57,36 30,19 0,39 28,68 2,64 60,38 0,38 413 16 
CQB 236 21,5 2475 80,51 64,41 0,58 28,81 3,39 43,22 2,12 233 11 
BIOCEN 69 6,3 44 21,74 26,09 0,07 10,14 0 57,97 0 111 0 
ICID 68 6,2 49 17,65 2,94 0,19 1,47 0 91,18 0 111 1 
CIE 58 5,3 117 53,45 1,72 0,12 17,24 0 65,52 0 157 2 
MEDSOL 51 4,6 68 25,49 9,8 0,09 5,88 0 19,61 0 66 0 
CENPALAB 46 4,2 126 50 8,7 0,27 17,39 2,17 65,22 0 104 0 
AICA 31 2,8 47 22,58 22,58 0,09 6,45 0 41,94 0 41 0 
LRESCUDERO 17 1,5 2 11,76 0 0,01 5,88 0 0 0 10 0 
CHP 15 1,4 10 13,33 40 0,1 0 0 33,33 0 13 0 
EPB FINLAY 9 0,8 5 11,11 22,22 0,02 0 0 77,78 0 11 0 
ESPH APESANT 4 0,4 3 75 0 0,08 0 0 25 0 8 0 
LFO 4 0,4 1 25 0 0,05 0 0 25 0 9 0 
ENCOMED 1 0,1 0 0 0 0 0 0 100 0 1 0 
BCF 2908 264,4 22285 62 30,81 0,51 28,71 4,26 68,23 2,06 4079 113 
 
 
Producing more than 30 % of BioCubaFarma’s scientific output during the period 2003-
2013, and receiving 35 % of the citations to BioCubaFarma’s papers, CIGB was the leader 
institution with an annual productivity of 82 papers per year, followed by CNIC (47,8), 
and CIM (30,1). CIGB was also leader in STP and IK, covering 33 % of authors with 
contributions to BioCubaFarma’s literature indexed by Scopus, and the 53 % of articles 
cited in international patents. 
The Center of Biomolecular Chemistry (CQB, former Center of Pharmaceutical 
Chemistry and currently unified to IFINLAY) presented the best proportion of cited 
articles (80,5 %), and the highest percentage of international collaboration (64,4 %). 
Cuban Neuroscience Center (CNC) occupied the second place in both indicators (74,5 % 
and 53,1 %), but it was the leader in expected visibility (49 %) and the rest of the studied 
indicators: normalized impact (0,82), excellence (10,5 %), and excellence with leadership 
(5,1 %). Curiously, CNC’s scientific output was covered by Neurology and 
Neurosciences, two subject categories avoided by the current study. 
CNC, CIM, CIGB and CQB were the four most visible institutions, according to citation-
based indicators (Figure 5). CNC and CQB presented high values of international 
collaboration, while CIM and CIGB shown high values of leadership. 
 
Figure 5. Leadership, international collaboration, output in high visible journals, excellence and 
normalized impact of the most productive BioCubaFarma’s companies (Scopus, 2003-2013). 
 
 
 
In general, the most productive institutions presented high values of leadership. The Q1 
factor was not decisive in all cases in order to achieve a better citation-based performance. 
Only eight institutions had papers among the 10 % of the most cited articles of a 
discipline. From them, only seven were leaders in some of these papers. And only eight 
exhibited at least one paper cited in international patents. 
 
Conclusions 
Biopharmaceutical industry had a protagonist role in the Cuban science system during the 
current century. BioCubaFarma was the second most productive Cuban institution 
according to The SCImago Institutions Rankings (SIR), thanks to the scientific output 
developed by its enterprises during the pre-foundational period (2003-2013).  
Qualified human resources, innovative knowledge, leadership, high specialization in the 
field of vaccines development and non-dependence of international collaboration are 
strengths of the organization. However, the comparison with the 15 most productive 
multinational biopharmaceutical companies revealed strong relationships between values 
of expected and real visibility. Therefore, it is still necessary to increase the number of 
articles published in highly visible journals with the aim to achieve a better citation-based 
performance.  
More contributions from less-productive institutions, more clinical research published in 
medical journals and more collaboration with universities and health institutions could 
also have positive benefits for BioCubaFarma’s pipelines and portfolios. The use of the 
studied indicators in further analysis of Cuban biopharmaceutical industry will offer the 
opportunity to follow the evolution of BioCubaFarma since the foundation to the future 
stages of development. 
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